Study Summary
This trial will investigate if intravitreal topotecan is safe and effective at treating severe PVR in people with RRD. It's been used to treat retinoblastoma with no adverse events at doses of 5-30 micrograms per injection.
- Proliferative Vitreoretinopathy
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: 6 months or last follow-up
Trial Safety
Safety Progress
Trial Design
6 Treatment Groups
Pars plana vitrectomy
1 of 6
Pars plana vitrectomy with or without scleral buckle
1 of 6
Pars plana vitrectomy and/or scleral buckle
1 of 6
Intravitreal topotecan with pars plana vitrectomy
1 of 6
Intravitreal topotecan with pars plana vitrectomy with or without scleral buckle
1 of 6
Intravitreal topotecan with pars plana vitrectomy and/or scleral buckle
1 of 6
Active Control
Experimental Treatment
50 Total Participants · 6 Treatment Groups
Primary Treatment: Intravitreal topotecan with pars plana vitrectomy · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What is the maximum number of participants permitted in this experiment?
"Affirmative. Based on the information furnished by clinicaltrials.gov, this medical trial is actively searching for volunteers to participate in its research. This study was posted on February 23rd 2023 and last updated four days later; it requires 50 individuals from two different sites." - Anonymous Online Contributor
Are enrollment opportunities currently available for the trial?
"According to the information present on clinicaltrials.gov, this trial is actively seeking participants. First posted on February 23rd 2023, it has recently been updated as of February 27th 2023." - Anonymous Online Contributor
Has the combination of Intravitreal topotecan and pars plana vitrectomy been given a clearance by the Food and Drug Administration?
"Given the lack of data regarding efficacy, Intravitreal topotecan with pars plana vitrectomy was assigned a safety score of 2." - Anonymous Online Contributor